188 related articles for article (PubMed ID: 38345160)
1. Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies.
Woost PG; William BM; Cooper BW; Ueda Oshima M; Otegbeye F; De Lima MJ; Wald D; Mahfouz RZ; Saunthararajah Y; Stefan T; Jacobberger JW
Cytometry B Clin Cytom; 2024 Jan; 106(1):11-24. PubMed ID: 38345160
[TBL] [Abstract][Full Text] [Related]
2. A pharmacodynamic assay to monitor treatment with the hypomethylating cytosine analogs, decitabine and azacitidine.
Jacobberger JW; Woost PG
Methods Cell Biol; 2024; 186():131-150. PubMed ID: 38705597
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.
Hur EH; Jung SH; Goo BK; Moon J; Choi Y; Choi DR; Chung YJ; Lee JH
Oncotarget; 2017 Feb; 8(7):11748-11762. PubMed ID: 28052028
[TBL] [Abstract][Full Text] [Related]
4. Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia.
Tang L; Kong Y; Wang H; Zou P; Sun T; Liu Y; Zhang J; Jin N; Mao H; Zhu X; Wang J; Meng F; You Y
Front Immunol; 2023; 14():1145441. PubMed ID: 37180104
[TBL] [Abstract][Full Text] [Related]
5. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T; Chinen T; Nishiyama A; Asada S; Shimura R; Isobe T; Yamamoto K; Sato N; Enomoto Y; Tanaka Y; Fukuyama T; Satoh H; Kato K; Saitoh K; Ishikawa T; Soga T; Nannya Y; Fukagawa T; Nakanishi M; Kitagawa D; Kitamura T; Goyama S
Cell Rep; 2023 Sep; 42(9):113098. PubMed ID: 37714156
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
[TBL] [Abstract][Full Text] [Related]
7. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network.
Gu X; Tohme R; Tomlinson B; Sakre N; Hasipek M; Durkin L; Schuerger C; Grabowski D; Zidan AM; Radivoyevitch T; Hong C; Carraway H; Hamilton B; Sobecks R; Patel B; Jha BK; Hsi ED; Maciejewski J; Saunthararajah Y
Leukemia; 2021 Apr; 35(4):1023-1036. PubMed ID: 32770088
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
Saunthararajah Y; Sekeres M; Advani A; Mahfouz R; Durkin L; Radivoyevitch T; Englehaupt R; Juersivich J; Cooper K; Husseinzadeh H; Przychodzen B; Rump M; Hobson S; Earl M; Sobecks R; Dean R; Reu F; Tiu R; Hamilton B; Copelan E; Lichtin A; Hsi E; Kalaycio M; Maciejewski J
J Clin Invest; 2015 Mar; 125(3):1043-55. PubMed ID: 25621498
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.
Bohl SR; Bullinger L; Rücker FG
Expert Rev Hematol; 2018 May; 11(5):361-371. PubMed ID: 29543073
[TBL] [Abstract][Full Text] [Related]
10. A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.
Hill B; Jagadeesh D; Pohlman B; Dean R; Parameswaran N; Chen J; Radivoyevitch T; Morrison A; Fada S; Dever M; Robinson S; Lindner D; Smith M; Saunthararajah Y
Semin Hematol; 2021 Jan; 58(1):35-44. PubMed ID: 33509441
[TBL] [Abstract][Full Text] [Related]
11. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal.
Ghoshal K; Datta J; Majumder S; Bai S; Kutay H; Motiwala T; Jacob ST
Mol Cell Biol; 2005 Jun; 25(11):4727-41. PubMed ID: 15899874
[TBL] [Abstract][Full Text] [Related]
12. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
[TBL] [Abstract][Full Text] [Related]
13. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
Schmelz K; Wagner M; Dörken B; Tamm I
Int J Cancer; 2005 May; 114(5):683-95. PubMed ID: 15609309
[TBL] [Abstract][Full Text] [Related]
14. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
[TBL] [Abstract][Full Text] [Related]
15. Silencing HO-1 sensitizes SKM-1 cells to apoptosis induced by low concentration 5-azacytidine through enhancing p16 demethylation.
Wang P; Ma D; Wang J; Fang Q; Gao R; Wu W; Lu T; Cao L
Int J Oncol; 2015 Mar; 46(3):1317-27. PubMed ID: 25585641
[TBL] [Abstract][Full Text] [Related]
16. An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.
Solly F; Koering C; Mohamed AM; Maucort-Boulch D; Robert G; Auberger P; Flandrin-Gresta P; Adès L; Fenaux P; Kosmider O; Tavernier-Tardy E; Cornillon J; Guyotat D; Campos L; Mortreux F; Wattel E
Clin Cancer Res; 2017 Jun; 23(12):3025-3034. PubMed ID: 27881579
[No Abstract] [Full Text] [Related]
17. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Oellerich T; Schneider C; Thomas D; Knecht KM; Buzovetsky O; Kaderali L; Schliemann C; Bohnenberger H; Angenendt L; Hartmann W; Wardelmann E; Rothenburger T; Mohr S; Scheich S; Comoglio F; Wilke A; Ströbel P; Serve H; Michaelis M; Ferreirós N; Geisslinger G; Xiong Y; Keppler OT; Cinatl J
Nat Commun; 2019 Aug; 10(1):3475. PubMed ID: 31375673
[TBL] [Abstract][Full Text] [Related]
18. Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes.
Straube J; Lane SW; Vu T
Bioessays; 2021 Oct; 43(10):e2100125. PubMed ID: 34463368
[TBL] [Abstract][Full Text] [Related]
19. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
[TBL] [Abstract][Full Text] [Related]
20. Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cells.
Vispé S; Deroide A; Davoine E; Desjobert C; Lestienne F; Fournier L; Novosad N; Bréand S; Besse J; Busato F; Tost J; De Vries L; Cussac D; Riond J; Arimondo PB
Oncotarget; 2015 Jun; 6(17):15265-82. PubMed ID: 25948775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
